Shares of Smith & Nephew plc (LON:SN) have been given a consensus recommendation of “Hold” by the twelve analysts that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is GBX 1,288.18 ($16.64).

Several research firms have commented on SN. Citigroup Inc. reiterated a “sell” rating and set a GBX 1,160 ($14.98) price objective on shares of Smith & Nephew plc in a research note on Thursday, June 22nd. Deutsche Bank AG reiterated a “hold” rating and set a GBX 1,200 ($15.50) price objective on shares of Smith & Nephew plc in a research note on Friday, July 28th. Jefferies Group LLC boosted their price objective on Smith & Nephew plc from GBX 1,350 ($17.44) to GBX 1,515 ($19.57) and gave the stock a “buy” rating in a research note on Friday, July 28th. Credit Suisse Group reiterated a “neutral” rating and set a GBX 1,280 ($16.53) price objective on shares of Smith & Nephew plc in a research note on Friday, July 28th. Finally, Berenberg Bank reiterated a “hold” rating and set a GBX 1,300 ($16.79) price objective on shares of Smith & Nephew plc in a research note on Tuesday, July 18th.

Smith & Nephew plc (LON SN) opened at 1399.00 on Friday. The company’s market capitalization is GBX 12.25 billion. The company’s 50-day moving average price is GBX 1,356.38 and its 200-day moving average price is GBX 1,305.19. Smith & Nephew plc has a 52 week low of GBX 1,064.91 and a 52 week high of GBX 1,407.00.

The firm also recently disclosed a dividend, which will be paid on Wednesday, November 1st. Investors of record on Thursday, October 5th will be issued a $0.12 dividend. This represents a yield of 0.72%. The ex-dividend date is Thursday, October 5th.

ILLEGAL ACTIVITY WARNING: “Smith & Nephew plc (SN) Given Consensus Recommendation of “Hold” by Brokerages” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/09/smith-nephew-plc-sn-given-consensus-recommendation-of-hold-by-brokerages.html.

In other Smith & Nephew plc news, insider Virginia Bottomley acquired 223 shares of the firm’s stock in a transaction that occurred on Wednesday, August 16th. The shares were purchased at an average cost of GBX 1,380 ($17.82) per share, for a total transaction of £3,077.40 ($3,974.43).

About Smith & Nephew plc

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.

Analyst Recommendations for Smith & Nephew plc (LON:SN)

Receive News & Ratings for Smith & Nephew plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew plc and related companies with MarketBeat.com's FREE daily email newsletter.